Switching rheumatoid arthritis treatments: An update

Autoimmunity Reviews

Volumn 10, Issue 7, 2011, Pages 397-403

  Atzeni, Fabiola ^a,b   Sarzi Puttini, Piercarlo ^a   Gorla, Roberto ^c   Marchesoni, Antonio ^d   Caporali, Roberto ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Rheumatology and Clinical Immunology Unit   (Italy)

^d UOC Day Hospital of Rheumatology   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anti TNF agents; Failure; Switching

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955121022     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.01.001     Document Type: Review

References (45)

1. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
2. Mikuls T.R., Saag K.G., Criswell L.A., Merlino L.A., Kaslow R.A., Shelton B.J., et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002, 61:994-999.
3. Pincus T., Kavanaugh A., Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the 'side effects' or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004, 22(suppl 35):S2-S11.
4. Weinblatt M.E., Coblyn J.S., Fox D.A., Fraser P.A., Holdsworth D.E., Glass D.N., Trentham D.E. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
5. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69(6):964-975.
6. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69:1898-1906.
7. Atzeni F., Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 2009, 10:1204-1211.
8. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
9. Singh J.A., Noorbaloochi S., Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol 2010, 37:1096-1104.
10. Patel A.M., Moreland L.W. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol 2010, 6:855-866.
11. Wiens A., Venson R., Correr C.J., Otuki M.F., Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010, 30:339-353.
12. Nam J., Emery P. Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod Rheumatol 2010, 20:325-330.
13. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000, 343:1594-1602.
14. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
15. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor ? monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
16. Finckh A., Simard J.F., Gabay C., Guerne P.A. Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis. Ann Rheum Dis 2008, 67:746-752.
17. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009, 11(Suppl 1):S1.
18. Smolen J.S., Kay J., Doyle M.K., Landewe R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
19. van Vollenhoven R., Harju A., Brannemark S., Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003, 62:1195-1198.
20. Haraoui B., Keystone E.C., Thorne J.C., Pope J.E., Chen I., Asare C.G., et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356-2359.
21. Hansen K.E., Hildebrand J., Genovese M.C., Cush J.J., Patel S., Cooley D.A., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098-1102.
22. Gómez-Puerta J.A., Sanmartí R., Rodríguez-Cros J.R., Cañete J.D. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004, 63:896.
23. Wick M., Ernestam S., Lindblad S., Bratt J., Klareskog L., van Vollenhoven R.F. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy to infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005, 34:353-358.
24. Cohen G., Courvoisier N., Cohen J.D., Zaltni S., Sany J., Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:795-800.
25. Hyrich K., Lunt M., Watson K., Symmons D.P., Silman A.J. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:13-20.
26. Di Poi E., Perin A., Morassi M., Del Frate M., Ferraccioli G.F., De Vita S. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007, 25:85-87.
27. Nikas S., Voulgari P., Alamanos Y., Papadopoulos C.G., Venetsanopoulou A.I., Georgiadis A.N., et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative study. Ann Rheum Dis 2006, 65:257-260.
28. van der Bijl A.E., Breedveld F.C., Antoni C.E., Kalden J.R., Kary S., Burmester G.R., et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028.
29. Buch M., Bingham S., Bejarano V., Bryer D., White J., Reece R., et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007, 57:448-453.
30. Caporali R., Sarzi-Puttini P., Atzeni F., Gorla R., Filippini M., Marchesoni A., et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010, 9:465-469.
31. Furst D.E., Gaylis N., Bray V., Olech E., Yocum D., Ritter J., et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study. Ann Rheum Dis 2007, 66:893-899.
32. Hjardem E., Østergaard M., Pødenphant J., Tarp U., Andersen L.S., Bing J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 2007, 66:1184-1189.
33. Laas K., Peltomaa R., Kautiainen H., Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:927-932.
34. Solau-Gervais E., Laxenaire N., Cortet B., Dubucquoi S., Duquesnoy B., Flipo R.M. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006, 45:1121-1124.
35. Scrivo R., Conti F., Spinelli F.R., Truglia S., Magrini L., Di Franco M., et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009, 61(2):107-117.
36. Gomez-Reino J.J., Carmona L., BIOBADASER GROUP Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8:R29.
37. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K., et al. Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007, 46:1191-1199.
38. Iannone F., Trotta F., Montecucco C., Giacomelli R., Galeazzi M., Matucci-Cerinic M., et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007, 66:249-252.
39. Kishimoto M., Greenberg J., Abramson S.B., Harrington T., Olenginski T.P., Kafka S.P., et al. Drug survival time on anti-TNF agents: does prior anti-TNF use influence RA outcomes? [Abstract]. Arthritis Rheum 2005, 52(suppl):S347.
40. Ang H.T.S., Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor- antagonists in patients with rheumatoid arthritis?. J Rheumatol 2003, 30:2315-2318.
41. Bennett A.N., Peterson P., Zain A., Grumley J., Panayi G., Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005, 44:1026-1031.
42. Hyrich K.L., Lunt M., Dixon W.G., Watson K.D., BSR Biologics Register Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008, 47(7):1000-1005.
43. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1339-1344.
44. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
45. Isaacs J.D. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opin Biol Ther 2009, 9:1463-1475.